Back to all studies
CompletedNCT05686239

Safety and Efficacy of RL-007 for schizophrenia

This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing Safety and Efficacy of RL-007 for schizophrenia.

Schizophrenia, Cognitive ImpairmentBehavioralFrom 18 Years to 55 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether RL-007 (Inidascamine) may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive RL-007 (Inidascamine), attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Czechia, and in Poland.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: December 8, 2022
Recruitment status
Completed
Enrollment listed in the registry
242
Sponsor
Recognify Life Sciences
Sponsor type
Unknown or unclear
Study type
Behavioral
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Czechia, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT05686239
Official title
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Bulgaria · 7 sites
  • Recognify Research Site
    Burgas
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Kardzhali
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Pleven
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Plovdiv
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Sofia
    Site status: Not listed — confirm with the team
  • Recognify Research Site (a)
    Varna
    Site status: Not listed — confirm with the team
  • Recognify Research Site (b)
    Varna
    Site status: Not listed — confirm with the team
Czechia · 3 sites
  • Recognify Research Site
    Pilsen
    Site status: Not listed — confirm with the team
  • Recognify Research Site (a)
    Prague
    Site status: Not listed — confirm with the team
  • Recognify Research Site (b)
    Prague
    Site status: Not listed — confirm with the team
Poland · 6 sites
  • Recognify Research Site
    Gdansk
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Gorlice
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Kielce
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Lodz
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Lublin
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Poznan
    Site status: Not listed — confirm with the team
United States · 20 sites
  • Recognify Research Site
    Culver City, California
    Site status: Not listed — confirm with the team
  • Collaborative Neuroscience Research
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Lafayette, California
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Oceanside, California
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Orange, California
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Torrance, California
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Hialeah, Florida
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Miami Lakes, Florida
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Augusta, Georgia
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Gaithersburg, Maryland
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Berlin, New Jersey
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Brooklyn, New York
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Chapel Hill, North Carolina
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Cincinnati, Ohio
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Cleveland, Ohio
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Dallas, Texas
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Houston, Texas
    Site status: Not listed — confirm with the team
  • Recognify Research Site
    Everett, Washington
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT05686239. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring psychotherapy or therapy for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

What is a behavioral study?

This appears to be a behavioral / psychological / psychosocial study involving RL-007 (Inidascamine), Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may take part in sessions or exercises related to habits, thoughts, emotions, or behaviors. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Could this study affect my mood, habits, motivation, or stress?

Behavioral studies can involve habits, emotions, motivation, stress, sleep, or ways of thinking. Ask whether the intervention could affect your mood or stress, and who to contact if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Recognify Life Sciences, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me